Hoth Therapeutics has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia.
Hoth's proposed study will be a Randomized, Double-Blind, Vehicle Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"Thanks to the hard work of our team and CRO partner Novotech, this ethics submission is yet another important step in the Company's clinical development program," Robb Knie, Chief Executive Officer of Hoth, said.
BioLexa is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach in treating atopic dermatitis.